Quectel Unveils Next Generation SG885G-WF Android Smart Module Ideal for High-Performance Industrial and Consumer IoT Applications
24.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today launches its new generation flagship Android smart module, the SG885G-WF. With high performance and rich media functions, the smart module is ideal for industrial and consumer applications that require high processing power and multimedia functions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724716405/en/
Quectel unveils next generation SG885G-WF Android smart module ideal for high-performance industrial and consumer IoT applications. (Photo: Business Wire)
The module is powered by the Qualcomm® QCS8550 System-on-Chip (SoC) for IoT from Qualcomm Technologies, Inc., delivering an impressive combination of flexibility and performance. It supports Wi-Fi 7, Bluetooth 5.3, and incorporates 2x2 Wi-Fi MIMO technology, providing users with enhanced connectivity options.
“Qualcomm Technologies is proud to collaborate with Quectel on their SG885G-WF to bring high performance connectivity solutions to consumers,” stated Dev Singh, Vice President, Business Development, Qualcomm Technologies, Inc. “Utilizing Quectel’s extensive infrastructure of cellular modules, the SG855G-WF exemplifies the necessary capabilities needed to adapt to tomorrow’s technology in IoT and beyond.”
With computing power of up to 48 TOPS, the module offers robust video capabilities, including video encoding at 4K at 120 fps or 8K at 30 fps, as well as video decoding at 4K at 240 fps or 8K at 60 fps. This ensures smooth and high-quality video processing for various applications.
Measuring 49.0mm x 51.0mm x 4.25mm, the SG885G-WF is suitable for global deployments and offers 12 GB LPDDR5X plus 256GB UFS memory. In addition, the module offers a rich set of interfaces that include LCM, camera, I2S, PCIe, UART, USB, I2C and SPI. These, in addition to adoption of the Android operating system, extend the module’s applicability to wide range of IoT and M2M applications including videoconferencing systems, live streaming devices, gaming, computing, robots, drones, AR/VR, intelligent retail and safety.
Quectel provides a range of high-performance antennas that greatly enhance wireless connectivity, aiming to assist customers in streamlining their design processes. By combining Quectel's antennas with the SG885G-WF Android Smart module, IoT developers can effectively reduce both time-to-market and costs associated with their IoT devices.
Moreover, the module offers the advantage of seamless integration with Quectel's range of cellular modules, enhancing connectivity, flexibility, and integration possibilities even further.
“We’re proud to launch our new flagship Android smart module with the new generation Quectel SG885G-WF,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “The powerful Qualcomm chipset along with support for Wi-Fi 7, Bluetooth 5.3 and 2x2 MIMO technology provides customers with a powerful module that offers connectivity choice and a wide variety of interfaces. As IoT matures, the ability to enable applications that need high processing power for AI and multimedia functions has become essential and the SG885G-WF has been designed to meet these needs.”
The Quectel SG885G-WF also offers three high-current flash LED drivers which support both flash and torch modes in addition to charging management capability which supports battery voltage detection, fuel gauge and battery temperature detection. Audio interfaces include SWR, digital microphone, MI2S and HIFI I2S.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230724716405/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom